Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Carcinoma, Non-Small-Cell Lung 4Breast Neoplasms 3Neoplasms 2Neoplasm Metastasis 2Melanoma 2Advanced Malignancies 2Urothelial Cancer 1Thyroid Neoplasms 1Solid Tumors, KRAS Mutation 1Sarcoma, Synovial 1Sarcoma, Alveolar Soft Part 1Sarcoma 1Prostatic Neoplasms 1Prostate Cancer Metastatic 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Opioid-Related Disorders 1Lung Neoplasms 1Liposarcoma 1Leukemia, Myeloid, Acute 1Leukemia, Biphenotypic, Acute 1Leukemia 1Leiomyosarcoma 1KRAS p.G12C Mutant Advanced Solid Tumors 1Hematologic Neoplasms 1Healthy Adult Participants 1Glioma 1Gastrointestinal Stromal Tumors 1Colorectal Neoplasms 1Central Nervous System Neoplasms 1Cancer Pain 1

Interventions

Cytarabine 21Cyclophosphamide 21fludarabine 18Whole-Body Irradiation 18venetoclax 15fludarabine phosphate 15Specimen Handling 15Methotrexate 15Mycophenolic Acid 13Vincristine 9Biopsy 9merphos 8Granulocyte Colony-Stimulating Factor 8Filgrastim 8Dexamethasone 8calaspargase pegol 7blinatumomab 7Stem Cell Transplantation 7Peripheral Blood Stem Cell Transplantation 7Hydrocortisone 7Busulfan 7Azacitidine 7revumenib 6Tacrolimus 6Melphalan 6Idarubicin 6Daunorubicin 6Asparaginase 6X-Rays 5Thiotepa 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Leukemia, Biphenotypic, Acute × Midazolam × 1 year × Clear all
NCT04067336 2026-05-13

First in Human Study of Ziftomenib in Relapsed or Refractory Acute Myeloid Leukemia

Kura Oncology, Inc.

Phase 1/2 Active not recruiting
263 enrolled 1 FDA
LymphoidOther hematologic neoplasm

Leukemia, Leukemia, Biphenotypic, Acute, Leukemia, Myeloid, Acute, Hematologic Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡